Patent ID: 8173689

Claim:
A method of treating a CSF-1R mediated disorder wherein the disorder is osteoporosis in a human or animal subject, comprising administering to the human or animal subject compound of Formula (I) or a pharmaceutically acceptable salt thereof effective to inhibit CSF-1R activity in the human or animal subject, wherein wherein X is O, S, or S(O); R 1 is wherein the dashed lines are saturated bonds; wherein L is a covalent bond, alkylidene, or substituted alkylidene; and R 10 , R 11 , and R 12 are independently selected from the group consisting of hydrogen, halo, hydroxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, and substituted amino; or R 11 is taken together with R 12 to form an aryl ring; R 2 is H or methyl; R 3 is selected from the group consisting of carbonitrile, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, acylamino, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl; each R 6 is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, or halo; n is 0, 1, or 2; and when X is O, R 4 is hydrogen, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and R 5 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aminocarbonyl, halo, heteroaryl, substituted heteroaryl, cycloalkyl, or substituted cycloalkyl; and when X is S or S(O), R 4 is hydrogen, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and R 5 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aminocarbonyl, halo, heteroaryl, substituted heteroaryl, cycloalkyl, or substituted cycloalkyl.